1. Home
  2. KODK vs INBX Comparison

KODK vs INBX Comparison

Compare KODK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Kodak Company

KODK

Eastman Kodak Company

HOLD

Current Price

$12.32

Market Cap

1.1B

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

BUY

Current Price

$75.49

Market Cap

999.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
KODK
INBX
Founded
1880
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
999.7M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
KODK
INBX
Price
$12.32
$75.49
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$150.00
AVG Volume (30 Days)
1.6M
191.1K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,114,000,000.00
$1,300,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
550.00
52 Week Low
$4.94
$10.90
52 Week High
$12.34
$94.57

Technical Indicators

Market Signals
Indicator
KODK
INBX
Relative Strength Index (RSI) 83.00 56.90
Support Level $5.93 $71.31
Resistance Level N/A $85.97
Average True Range (ATR) 0.80 4.88
MACD 0.36 1.54
Stochastic Oscillator 98.91 82.52

Price Performance

Historical Comparison
KODK
INBX

About KODK Eastman Kodak Company

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: